Answers are grounded in this paper and cite their sources.
Purpose While immune checkpoint inhibitors (ICIs) have improved survival in advanced non-small cell lung cancer (NSCLC), therapeutic benefits vary and current biomarkers are often costly or static. This study evaluated the associations of baseline and dynamic immune-inflammation-nutrition (IIN) biomarkers with clinical outcomes to develop a composite predictive score (INICS). Materials and Methods We retrospectively analyzed 109 patients with driver-negative advanced NSCLC (68 receiving ICIs plus chemotherapy; 41 receiving platinum-based doublet chemotherapy). IIN biomarkers, including lymphocyte-to-monocyte ratio (LMR), prognostic nutritional index (PNI), and platelet-to-lymphocyte ratio (PLR), among others, were measured at baseline and week 6. Dynamic changes were defined as Δ (week 6 − baseline). The Immune-Inflammation-Nutrition Composite Score (INICS) was derived based on baseline LMR, PNI, and Δ PLR. Results Baseline characteristics were comparable between groups except for pathological type. Overall survival (OS) was significantly longer in the ICI group ( P < 0.05). In the ICI cohort, higher baseline LMR independently predicted better objective response ( P < 0.05), while higher baseline PNI and albumin correlated with improved disease control ( P < 0.05). Disease control was associated with significant decreases in PLR and systemic immune-inflammation index (SII) during treatment ( P < 0.05). The INICS was independently associated with progression-free survival (PFS) (HR, 0.46; 95% CI, 0.26–0.81; P = 0.008), with a 12-month time-dependent AUC of 0.674. Conclusion The INICS, integrating baseline IIN status and early dynamic inflammatory response, serves as a robust independent predictor of PFS in advanced NSCLC patients treated with ICIs, offering potential for clinical risk stratification. Clinical Trial Registration Not applicable. This was a retrospective observational cohort study and does not meet the definition of a clinical trial requiring registration.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: